KSPHF: AI 评分 50/100 — AI 分析 (4月 2026)

Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company focused on researching, developing, manufacturing, and selling specialized drugs. The company's pipeline includes treatments for dysuria, type 2 diabetes, renal anemia, overactive bladder, and other conditions, primarily serving the Japanese market.

Key Facts: AI Score: 50/100 Sector: Healthcare

公司概况

概要：

Kissei Pharmaceutical Co., Ltd., based in Japan, develops and markets specialty pharmaceutical products, focusing on therapeutic areas like dysuria, diabetes, and renal anemia. With a strong presence in the domestic market, Kissei leverages its research and development pipeline to address unmet medical needs and maintain a competitive edge in the generic drug sector.

KSPHF是做什么的？

Kissei Pharmaceutical Co., Ltd., established in 1946 and headquartered in Matsumoto, Japan, has evolved into a research-driven pharmaceutical company. Originally named Kissei Yakuhin Kogyo Co., Ltd., the company adopted its current name in 1964. Kissei focuses on the development, manufacture, and sale of pharmaceutical products, primarily within Japan. Its product portfolio includes Urief and Urief OD tablets for dysuria, Glufast, Glubes, and Marizev tablets for type 2 diabetes, Darbepoetin Alfa BS and Epoetin Alfa BS injections for renal anemia, Beova tablets for overactive bladder, P-TOL chewable tablets for hyperphosphatemia, and Minirin Melt OD tablets for nocturia. The company's pipeline features several drugs in Phase III clinical trials, targeting conditions such as spinocerebellar ataxia, microscopic polyangiitis, ulcerative colitis, chronic idiopathic thrombocytopenic purpura, and uremic pruritus. Additionally, Kissei is developing treatments for endometriosis, uterine fibroids, Parkinson's disease, and asthma. Beyond pharmaceuticals, Kissei also produces and sells protein-controlled and energy-supply foods, along with related materials. The company provides system development, information processing, construction contracting, equipment and facility management, and information gathering and development support services.

KSPHF的投资论点是什么？

Kissei Pharmaceutical Co., Ltd. presents a compelling investment case based on its established presence in the Japanese pharmaceutical market and a diversified pipeline of drugs targeting various therapeutic areas. With a P/E ratio of 13.18 and a profit margin of 14.8%, the company demonstrates financial stability. Key growth catalysts include the potential approval and commercialization of drugs in Phase III clinical trials, such as KPS-0373 for spinocerebellar ataxia and AJM300 for ulcerative colitis. The company's dividend yield of 2.34% offers an additional incentive for investors. However, potential risks include regulatory hurdles, competition from generic drug manufacturers, and the inherent uncertainty associated with pharmaceutical research and development.

KSPHF在哪个行业运营？

Kissei Pharmaceutical Co., Ltd. operates in the competitive Japanese pharmaceutical market, characterized by a growing aging population and increasing demand for specialized treatments. The industry is driven by innovation, regulatory approvals, and pricing pressures. Kissei competes with both domestic and international pharmaceutical companies, including BIOGY, CHIZF, CMOPF, EVOTF, and LJUIF, focusing on niche therapeutic areas and generic drugs. The market is also influenced by government healthcare policies and reimbursement rates, which impact the profitability of pharmaceutical companies.

Drug Manufacturers - Specialty & Generic

Healthcare

KSPHF有哪些增长机遇？

Expansion of Product Portfolio: Kissei has several products in Phase III clinical trials, including KPS-0373 for spinocerebellar ataxia and AJM300 for ulcerative colitis. Successful completion of these trials and subsequent regulatory approvals could significantly expand Kissei's product portfolio and revenue streams. The market for spinocerebellar ataxia treatments is estimated to grow, driven by increasing awareness and diagnosis rates. Timeline: 2027-2028.
Geographic Expansion: While Kissei primarily operates in Japan, there is potential for geographic expansion into other Asian markets or through partnerships with international pharmaceutical companies. Expanding into new markets could diversify Kissei's revenue base and reduce its reliance on the Japanese market. The Asian pharmaceutical market is experiencing rapid growth, driven by increasing healthcare expenditure and access to medicines. Timeline: 2028-2030.
Strategic Alliances and Partnerships: Kissei can pursue strategic alliances and partnerships with other pharmaceutical companies to co-develop and co-market drugs. This could accelerate the development and commercialization of new products and expand Kissei's market reach. Collaborations can also provide access to new technologies and expertise. Timeline: Ongoing.
Focus on Specialty Drugs: Kissei's focus on specialty drugs, particularly in areas like dysuria, diabetes, and renal anemia, positions it well to capitalize on the growing demand for targeted therapies. Specialty drugs often command higher prices and offer greater profit margins compared to generic drugs. The global market for specialty drugs is projected to grow, driven by advances in biotechnology and personalized medicine. Timeline: Ongoing.
Investment in Research and Development: Kissei's commitment to research and development is crucial for maintaining a competitive edge in the pharmaceutical industry. Continued investment in R&D can lead to the discovery and development of innovative new drugs and therapies. A strong R&D pipeline is essential for long-term growth and value creation. Timeline: Ongoing.

Market capitalization of $1.07 billion, reflecting a substantial valuation in the specialty pharmaceutical sector.
P/E ratio of 13.18, indicating a potentially undervalued stock compared to industry peers.
Profit margin of 14.8%, demonstrating efficient operations and profitability.
Gross margin of 48.2%, showcasing strong pricing power and cost management.
Dividend yield of 2.34%, providing a steady income stream for investors.

KSPHF提供哪些产品和服务？

Researches and develops pharmaceutical products.
Manufactures pharmaceutical products.
Sells pharmaceutical products, primarily in Japan.
Offers Urief and Urief OD tablets for the treatment of dysuria.
Provides Glufast, Glubes, and Marizev tablets for type 2 diabetes.
Offers Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia.
Develops and sells protein controlled and energy supply foods.
Offers system development and information processing services.

KSPHF如何赚钱？

Develops and patents pharmaceutical products.
Manufactures drugs for specific therapeutic areas.
Markets and sells drugs through established distribution channels in Japan.
Generates revenue through sales of prescription drugs and related healthcare products.

Patients with conditions such as dysuria, type 2 diabetes, and renal anemia.
Hospitals and clinics that prescribe and administer Kissei's drugs.
Pharmacies that dispense Kissei's drugs to patients.
Healthcare providers who recommend Kissei's products.

Patent protection for innovative drugs, providing exclusivity and pricing power.
Established brand reputation and relationships with healthcare providers in Japan.
Specialized knowledge and expertise in specific therapeutic areas.
Strong research and development capabilities, enabling the development of new drugs and therapies.

什么因素可能推动KSPHF股价上涨？

Upcoming: Potential regulatory approval and commercialization of KPS-0373 for spinocerebellar ataxia.
Upcoming: Potential regulatory approval and commercialization of AJM300 for ulcerative colitis.
Ongoing: Progress in clinical trials for other drugs in the pipeline, including treatments for microscopic polyangiitis and uremic pruritus.
Ongoing: Strategic alliances and partnerships with other pharmaceutical companies.
Ongoing: Expansion into new therapeutic areas and markets.

KSPHF的主要风险是什么？

Potential: Failure or delays in clinical trials for drugs in the pipeline.
Potential: Regulatory hurdles and delays in obtaining drug approvals.
Ongoing: Competition from generic drug manufacturers and pricing pressures.
Ongoing: Dependence on the Japanese pharmaceutical market.
Potential: Changes in government healthcare policies and reimbursement rates.

KSPHF的核心优势是什么？

Strong presence in the Japanese pharmaceutical market.
Diversified product portfolio targeting various therapeutic areas.
Robust pipeline of drugs in Phase III clinical trials.
Established relationships with healthcare providers and distributors.

KSPHF的劣势是什么？

Limited geographic diversification, primarily focused on Japan.
Dependence on regulatory approvals for new drug launches.
Exposure to pricing pressures from generic drug manufacturers.
Potential for clinical trial failures and delays.

KSPHF有哪些机遇？

Expansion into new therapeutic areas and markets.
Strategic alliances and partnerships with other pharmaceutical companies.
Increased demand for specialty drugs and targeted therapies.
Growing aging population in Japan and increasing healthcare expenditure.

KSPHF面临哪些威胁？

Competition from domestic and international pharmaceutical companies.
Changes in government healthcare policies and reimbursement rates.
Patent expirations and generic drug entry.
Economic downturns and fluctuations in currency exchange rates.

KSPHF的竞争对手是谁？

Biogen Inc. — Focuses on neurology and biotechnology. — (BIOGY)
Chiesi Farmaceutici S.p.A. — Specializes in respiratory and specialty care. — (CHIZF)
Cmo S.A. — Unknown differentiation. — (CMOPF)
Evotec SE — Drug discovery and development partnerships. — (EVOTF)
Lundbeck AS — Focuses on psychiatric and neurological disorders. — (LJUIF)

Key Metrics

MoonshotScore: 50/100

Company Profile

CEO: Mutsuo Kanzawa
Headquarters: Matsumoto, JP
Employees: 1,779
Founded: 2017

AI Insight

AI analysis pending for KSPHF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Kissei Pharmaceutical Co., Ltd. do?

Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that researches, develops, manufactures, and sells pharmaceutical products, primarily in Japan. The company focuses on specialty drugs for therapeutic areas such as dysuria, type 2 diabetes, renal anemia, and overactive bladder. Kissei's business model involves developing and patenting innovative drugs, manufacturing them, and marketing them through established distribution channels. The company also generates revenue through the sale of protein-controlled and energy-supply foods and related services.

What do analysts say about KSPHF stock?

AI analysis is pending for Kissei Pharmaceutical Co., Ltd. (KSPHF). Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is currently unavailable. Investors should consult with a financial advisor and conduct their own due diligence before making any investment decisions. Further information will be provided once the AI analysis is complete.

What are the main risks for KSPHF?

Kissei Pharmaceutical Co., Ltd. faces several risks, including the potential for clinical trial failures or delays, regulatory hurdles in obtaining drug approvals, and competition from generic drug manufacturers. The company's dependence on the Japanese pharmaceutical market also poses a risk, as changes in government healthcare policies and reimbursement rates could impact its profitability. Additionally, economic downturns and fluctuations in currency exchange rates could affect Kissei's financial performance.